Neomatrix — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Neomatrix is a private, preclinical-stage biotech focused on personalized cancer immunotherapy. The company has developed an integrated platform for identifying patient-specific tumor neoantigens and rapidly manufacturing synthetic DNA vaccines. With €1.5 million in new funding secured in late 2024 and backing from EU Horizon 2020, Neomatrix is advancing its regulatory development and preparing for clinical studies in melanoma and lung cancer, targeting a significant unmet need in oncology.

Oncology

Technology Platform

Integrated platform for personalized cancer DNA vaccines: combines neoantigen identification from patient tumors, innovative design/production of synthetic DNA vaccines, and a proprietary delivery system to maximize immune response, designed for synergy with checkpoint inhibitors.

Opportunities

The growing validation of neoantigen-based therapies and the large market for combination approaches with checkpoint inhibitors in melanoma and lung cancer present a significant opportunity.

Supportive EU grant funding and a cost-effective clinical environment in Italy can accelerate early development.

Risk Factors

High scientific risk as the unproven DNA vaccine platform must demonstrate safety and efficacy in humans.

Operational risk in executing complex personalized therapy trials and financial risk due to limited current funding, requiring a near-term larger raise in a competitive market.

Competitive Landscape

Neomatrix operates in a highly competitive space dominated by large-cap biotech (e.g., BioNTech, Moderna) and pharma companies with advanced mRNA and other neoantigen platforms. It must differentiate on speed, cost, or efficacy of its DNA-based approach and delivery technology.

More companies in Oncology (General) →More companies in Italy →